Accessibility navigation

Sequentially testing for a gene-drug interaction in a genomewide analysis

Kelly, P., Zhou, Y., Whitehead, J., Stallard, N. and Bowman, C. (2008) Sequentially testing for a gene-drug interaction in a genomewide analysis. Statistics in Medicine, 27 (11). pp. 2022-2034. ISSN 0277-6715

Full text not archived in this repository.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.1002/sim.3059


Assaying a large number of genetic markers from patients in clinical trials is now possible in order to tailor drugs with respect to efficacy. The statistical methodology for analysing such massive data sets is challenging. The most popular type of statistical analysis is to use a univariate test for each genetic marker, once all the data from a clinical study have been collected. This paper presents a sequential method for conducting an omnibus test for detecting gene-drug interactions across the genome, thus allowing informed decisions at the earliest opportunity and overcoming the multiple testing problems from conducting many univariate tests. We first propose an omnibus test for a fixed sample size. This test is based on combining F-statistics that test for an interaction between treatment and the individual single nucleotide polymorphism (SNP). As SNPs tend to be correlated, we use permutations to calculate a global p-value. We extend our omnibus test to the sequential case. In order to control the type I error rate, we propose a sequential method that uses permutations to obtain the stopping boundaries. The results of a simulation study show that the sequential permutation method is more powerful than alternative sequential methods that control the type I error rate, such as the inverse-normal method. The proposed method is flexible as we do not need to assume a mode of inheritance and can also adjust for confounding factors. An application to real clinical data illustrates that the method is computationally feasible for a large number of SNPs. Copyright (c) 2007 John Wiley & Sons, Ltd.

Item Type:Article
Divisions:Science > School of Mathematical, Physical and Computational Sciences > Department of Mathematics and Statistics > Applied Statistics
ID Code:9835
Uncontrolled Keywords:pharmacogenetics, clinical trials, group sequential designs, adaptive, designs, drug development, CASE-CONTROL ASSOCIATION, CLINICAL-TRIALS, P-VALUES, TRUNCATED PRODUCT, WIDE ASSOCIATION, DISEASE, DESIGN, MARKERS

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation